goodfellowsmansfield.com

Wednesday, May 30, 2007

New Zealander Folole Muliaga died Tuesday morning after Mercury Energy cut off the power in her household due to $168.40 of unpaid bills. Mrs Folole Muliaga was seriously ill and dependent on an oxygen life support machine that required electricity to run.

The 44-year-old died two and a half hours after the power was cut by a contractor, working for State Owned Enterprise, Mercury Energy. A spokesperson for Mercury Energy has said that they are devastated and deeply sympathetic by the news, but state they did not know that the power was needed to run the oxygen machine. They have stated that discretion is exercised in cases of extreme hardship or when medical conditions make it appropriate and that the same contractor had done so the previous day. However, relatives claim that the contractor was told that the power was needed by family members present, was invited into the house and talked to Mrs Folole Muliaga, but showed no discretion or compassion under the circumstances.

The power was cut at about 11am. Brendan Sheehan, spokesperson for the family, said that after the power was cut, Mrs Muliaga suffered from breathing difficulties. During this time Mrs Mulianga declined an offer for an ambulance from family members. At about 1pm she informed her sons that she was feeling dizzy and asked for hymns to be sung. Her condition quickly deteriorated until she couldn’t speak. When she passed out at 1:32pm, an ambulance was called but Mrs Mulianga could not be revived when it arrived 12 minutes later.

That same evening remaining family members claim they had to grieve in the dark, power was only reconnected after the outstanding amount of $168.40 was paid to Mercury Energy. Mercury Energy claim that the were initially only made aware that a funeral was going to take place and attempted to reconnect the supply at midnight once the full circumstances were made clear but were unable to contact the family. They state the supply was eventually reconnected before 8am the next day. Evidence has been provided by family members to show that they had made two payments to Mercury Energy in the same month trying to clear their outstanding bill, $61.90 on 1 May 2007, and $45 on 17 May 2007.

Trevor Mallard, minister of State Owned Enterprises, said, “I do think it is important that the facts are established before people rush to judgement.”

Both the New Zealand Police and Mercury Energy, the retail operating division of Mighty River Power, are conducting investigations into the events.

The mother-of-four school teacher lived in Mangere, South Auckland and had been suffering from a heart and lung condition, according to relatives of Mrs Muliaga, since February.

Hospital doctors have expressed surprise at the short length of time between when the supply was cut and the death occurred. They have also explained that relatives are trained what to do if the supply is lost, including to call for an ambulance if severe symptoms develop.

Tuesday, September 20, 2005

US doctors are to interview 12 patients with a view to performing the first ever transplant of a human face.

The Cleveland Clinic will choose between seven women and five men to find the person most suited for the experimental procedure, which is a radical and controversial solution to extreme facial scarring or disfigurement.

Having practiced the procedure on bodies donated for medical research, the Cleveland Clinic team believe they have a 50% chance of success. The procedure will not live up to science-fiction predictions and give the recipient the appearance of the donor; the underlying bone structure is the deciding factor in the final appearance. The new face will end up resembling neither the donor nor recipient.

Surgeons in several other countries have announced being ready to perform this procedure in the past. However, the risk and non life-threatening nature of disfigurement have meant that gaining approval for the groundbreaking surgery has been difficult. Like many other transplant operations, the recipient would be required to take drugs to prevent tissue rejection for the remainder of their life. These drugs can have side effects and carry their own risks involving the patient’s immune system.

[edit]

Tuesday, January 25, 2011

The sole United States manufacturer of a key component of lethal injections announced Friday that it will cease production of the drug, contributing to shortages and delaying executions.

Sodium thiopental, the first of a three drug cocktail used in 34 states to render the prisoner to be executed unconscious, was manufactured in Italy until Italian authorities stated that they would only license the manufacture if it was used for medical purposes and not, crucially, for executions.

In a statement, the company, Hospira, said that they have never condoned the use of their drug, marketed as ‘Pentothal’, in executions, and that they could not “prevent the drug from being diverted to departments of corrections for use in capital punishment procedures”.

The move means that the United States is without a viable supplier for sodium thiopental. Although many European countries manufacture the drug, which is primarily used in Europe as an anæsthetic, no manufacturer has been found that is willing to supply it for use in conjunction with the death penalty, the abolition of which has been lobbied by the EU since 2008.

The shortage means that executions in California and Oklahoma have been delayed, with Texas’ last remaining stocks of the drug due to expire in March, weeks before two scheduled executions. These delays are likely to be prolonged as the legal process of drawing up new drugs to be used for injections is lengthy. Pentobarbital, an alternative which used at the Dignitas clinic in Switzerland, is used for lethal injections in Oregon, and has started to be used by Oklahoma.

Hospira’s decision caused mixed reactions throughout the medical community, with the American Society of Anesthesiologists stating Monday that sodium thiopental is an “important and medically necessary anesthetic agent” that is a “first-line anesthetic in many cases”, citing geriatric and cardiovascular conditions, among others. It said that, although they disagree with the death penalty, “we also do not condone using the issue as the basis to place undue burdens on the distribution of this critical drug to the United States. It is an unfortunate irony that many more lives will be lost or put in jeopardy as a result of not having the drug available for its legitimate medical use.”